Concurrently, LineaRx announced the signing of an exclusive North American licensing agreement and research services agreement with iCell Gene Therapeutics, Inc. (iCell) under which iCell licensed to LineaRx an anti-CD19 CAR T therapy for non-viral delivery.
LineaRx will utilise its NVPF platform, along with the in-licensed anti-CD19 CAR T therapy, to develop, manufacture and commercialize LinCART19, a non-viral, plasmid free anti-CD19 CAR T drug candidate.
The company believes its novel NVPF construction of CAR Ts provides a manufacturing format that would be attractive to many developers of these therapies.
Despite costly and inefficient manufacturing platforms, the CAR T market is currently experiencing rapid growth and investment, with over USD 20bn in recent M and A activity, and is expected to yield a CAGR of 32.5% at least through 20282.
The NVPF LineaRx CAR T manufacturing platform under development leverages Applied DNA's expertise in large-scale PCR-based production and chemical modification of DNA to produce expression vectors for CAR T therapy, without the use of viral vectors or plasmids.
CAR T therapies are a DNA based approach to destroy cancer cells by harnessing the power of a patient's own immune system. CD19 is a protein that is expressed on the vast majority of B cell cancers.
By targeting CD19 expressing B cells with CAR modified T cells, various B cell malignancies can be addressed. Since 2017, the FDA has approved two CAR T-based therapies targeting the CD19 epitope, opening a new frontier in the fight against cancer.
iCell Gene Therapeutics is developing proprietary technologies and a pipeline of Chimeric Antigen Receptor engineered cell therapies designed to be first in class, cost effective and life saving.
LineaRx seeks to commercialize the biotherapeutic value of Applied DNA's deep expertise and experience in the design, manufacture and chemical modification of DNA by large scale polymerase chain reaction.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT